Andy van Hateren
PhD
Senior Postdoctoral Scientist in Immunology
Research Interest
Major Histocompatibility Complex class I (MHC-I) molecules are a central part of the adaptive immune system. MHC-I molecules become loaded with peptides inside cells, before progressing to the cell surface where peptide-loaded MHC-I complexes are inspected by cytotoxic cells of the immune system. This can lead to the elimination of infected, or abnormal, cells depending on which peptide is bound by MHC-I.
My research is focused on understanding the process by which peptides may be selected for presentation by MHC-I molecules, while other peptides are not. This knowledge will underpin the modulation of MHC-I peptide selection for therapeutic benefits, such as vaccinations. My key research interests are:
Determining the molecular mechanisms by which tapasin and TAPBPR proteins modulate the selection of peptides for presentation by MHC-I molecules.
Understanding why some MHC-I molecules can select peptides without assistance from tapasin or TAPBPR.
Contrasting peptide selection in highly polymorphic classical MHC-I molecules (e.g. HLA-A, HLA-B, HLA-C) with that in virtually invariant non-classical MHC-I molecules (e.g. HLA-E).
Background
PhD: Professor Jim Kaufman’s lab, Institute for Animal Health, investigating the evolutionary history of the MHC. In my project, I provided a mechanistic basis for the molecular co-evolution of tapasin and MHC-I in the chicken MHC.
Postdoctoral research: Professor Tim Elliott’s lab, University of Southampton, investigating the molecular mechanisms of MHC-I peptide selection and tapasin function. Key collaborations: with Professor Louise Boyle, we characterised TAPBPR (for TAP-Binding-Protein-Related) as an MHC-I specific peptide editing chaperone; with Professor Paul Skipp (University of Southampton) we used hydrogen-deuterium exchange mass spectrometry experiments to characterise the dynamic profile of MHC-I molecules; with Professor Tony Purcell (Monash University, Australia), we provided the molecular basis of an MHC-I restricted drug hypersensitivity reaction.
Contributions to education: in my previous positions, I have delivered lectures, facilitated tutorials, lead the dissertation module of a postgraduate MSc course, supervised students (PhD, postgraduate, undergraduate), and was a personal academic tutor.
Recent publications
Genetic characterization of the TAPBP and its allelic association with BF2 in the chicken major histocompatibility complex.
Journal article
Fernando R. et al, (2026), Immunogenetics, 78
Evidence of focusing the MHC class I immunopeptidome by tapasin.
Journal article
Darley R. et al, (2025), Frontiers in immunology, 16
Atom-level mechanism of tapasin-independent peptide editing by Major Histocompatibility Complex class I molecules
Preprint
Turner S. et al, (2025)
Visualising tapasin- and TAPBPR-assisted editing of major histocompatibility complex class-I immunopeptidomes.
Journal article
van Hateren A. and Elliott T., (2023), Current opinion in immunology, 83
De-risking clinical trial failure through mechanistic simulation.
Journal article
Brown LV. et al, (2022), Immunotherapy advances, 2